Charting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkit
通过多组学单细胞工具包绘制 SF3B1 突变克隆造血 (CH) 和骨髓增生异常综合征 (MDS) 的分化拓扑图
基本信息
- 批准号:10366517
- 负责人:
- 金额:$ 69.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-15 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdmixtureAdoptedAffectAutomobile DrivingBar CodesBlood CellsBone MarrowCell physiologyCell surfaceCellsCellular Indexing of Transcriptomes and Epitopes by SequencingCharacteristicsChromatinClonal ExpansionComplementary DNADNADataDevelopmentDiseaseDysmyelopoietic SyndromesEpigenetic ProcessErythroidFrequenciesGene ExpressionGeneticGenetic TranscriptionGenomicsGenotypeGrowthHematological DiseaseHematologyHematopoiesisHematopoieticHematopoietic NeoplasmsHematopoietic stem cellsHumanIndividualKnowledgeLeadLengthLesionLinkMediatingMethodsMinorityMutateMutationNaturePatientsPatternPhenotypePlayPopulationProtein IsoformsProteinsRNARNA SplicingRNA analysisRNA-Binding ProteinsRecurrenceResolutionRiskRoleSamplingSignal TransductionSomatic MutationSpliceosomesSystemTechniquesTechnologyTestingTreesValidationVariantbasebone cellcell typechromatin modificationcohortdriver mutationhematopoietic differentiationinsightinterestmethylomemouse modelmultiple omicsmutantmutational statusprogenitorprogramsprotein expressionself-renewalsingle cell technologysingle-cell RNA sequencingtranscriptome
项目摘要
SUMMARY
Genomic analyses of thousands of MDS patients has established that mutations in RNA splicing factors are
the most common class of genetic alterations in patients with MDS. In parallel, functional studies have
revealed that several of these genetic lesions appear to drive aberrant hematopoietic self-renewal and
differentiation that is characteristic of MDS. Specifically, mutations in splicing factor 3b subunit 1(SF3B1), a
core spliceosome component, are among the most common in patients with MDS and lead to incorrect intronic
branch point recognition. Despite these advances, our knowledge of the effects of this genetic alteration on
downstream gene expression programs within actual disease initiating cells has been hampered by the
coexistence of normal wildtype hematopoiesis together with the aberrant clone harboring somatic driver
mutations. While some of these limitations are now beginning to be addressed with single cell genomics,
performing a layered genomic analysis to simultaneously capture somatic mutations, gene expression, RNA
splicing, and chromatin state in single cells has never been performed. Expression of RNA-binding proteins is
in turn cell type dependent, necessitating the simultaneously profiling of gene expression, full-length cDNA and
SF3B1 mutational status at the single cell level, allowing splicing to be examined in the proper cellular context.
To address this challenge, we developed an array of multi-omic single-cell technologies that are capable of
capturing multiple layers of information (e.g., genotypes, transcriptomes, methylomes, protein expression) from
the same single cells. Moreover, we addressed the specific challenge of genotyping in scRNA-seq in single
cells at high throughput by developing Genotyping of Transcriptomes (GoT). Importantly, GoT turns the
admixture of mutant and wildtype hematopoiesis from a limitation to an advantage, enabling the direct
comparison of mutant and wildtype cells within the same individual.
Capitalizing on a unique cohort of bone marrow samples from individuals with MDS and CH, we now aim to
apply and extend the multi-omics single-cell toolkit to test define how SF3B1 somatic mutations lead to clonal
growth advantage. First, we will perform GoT across MDS and CH samples with canonical SF3B1 driver
mutations. We will integrate GoT with Cellular Indexing of Transcriptomes and Epitopes by sequencing (CITE-
seq) (GoT-CITE), to add the critical layer of cell surface markers to single-cell whole transcriptomes. Second,
mutations in splicing factors are specifically associated with greater risk of transformation in CH. Therefore, we
will develop and implement GoT-Splice, where long-read sequencing will be used to define splicing variation
as a function of cell identity. Third, given the high importance of epigenetic patterning to hematopoietic stem
cell identity, we will develop and apply targeted single-cell genotyping in the context of chromatin accessibility
(GoT-ChA). This will allow us to unravel the regulatory underpinnings of SF3B1-driven CH and MDS.
概括
对数千名 MDS 患者的基因组分析表明,RNA 剪接因子的突变与
MDS 患者最常见的一类基因改变。与此同时,功能研究也
研究表明,其中一些遗传损伤似乎会驱动异常的造血自我更新和
分化是 MDS 的特征。具体来说,剪接因子 3b 亚基 1 (SF3B1) 的突变,
核心剪接体成分,是 MDS 患者中最常见的成分之一,会导致不正确的内含子
分支点识别。尽管取得了这些进展,我们对这种基因改变的影响的了解
实际疾病起始细胞内的下游基因表达程序已受到阻碍
正常野生型造血与携带体细胞驱动因子的异常克隆共存
突变。虽然其中一些限制现在开始通过单细胞基因组学得到解决,
进行分层基因组分析以同时捕获体细胞突变、基因表达、RNA
单细胞中的剪接和染色质状态从未进行过。 RNA结合蛋白的表达是
反过来,细胞类型依赖性,需要同时分析基因表达、全长 cDNA 和
单细胞水平的 SF3B1 突变状态,允许在适当的细胞环境中检查剪接。
为了应对这一挑战,我们开发了一系列多组学单细胞技术,这些技术能够
捕获多层信息(例如基因型、转录组、甲基化组、蛋白质表达)
相同的单细胞。此外,我们还解决了 scRNA-seq 中基因分型的具体挑战
通过开发转录组基因分型 (GoT) 以高通量细胞。重要的是,GoT 改变了
突变体和野生型造血的混合从限制变为优势,从而能够直接
同一个体内突变型和野生型细胞的比较。
利用来自 MDS 和 CH 患者的一组独特的骨髓样本,我们现在的目标是
应用并扩展多组学单细胞工具包来测试定义 SF3B1 体细胞突变如何导致克隆
增长优势。首先,我们将使用规范的 SF3B1 驱动程序跨 MDS 和 CH 样本执行 GoT
突变。我们将通过测序将 GoT 与转录组和表位的细胞索引整合起来 (CITE-
seq) (GoT-CITE),将细胞表面标记的关键层添加到单细胞全转录组中。第二,
剪接因子的突变与 CH 转化风险的增加特别相关。因此,我们
将开发和实施 GoT-Splice,其中长读长测序将用于定义剪接变异
作为细胞身份的函数。第三,鉴于表观遗传模式对造血干的高度重要性
细胞身份,我们将在染色质可及性的背景下开发和应用靶向单细胞基因分型
(GoT-ChA)。这将使我们能够解开 SF3B1 驱动的 CH 和 MDS 的监管基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Omar Abdel-Wahab其他文献
Omar Abdel-Wahab的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Omar Abdel-Wahab', 18)}}的其他基金
Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia
用于选择性靶向RNA剪接因子突变型白血病的合成内含子
- 批准号:
10722782 - 财政年份:2023
- 资助金额:
$ 69.8万 - 项目类别:
Charting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkit
通过多组学单细胞工具包绘制 SF3B1 突变克隆造血 (CH) 和骨髓增生异常综合征 (MDS) 的分化拓扑图
- 批准号:
10570240 - 财政年份:2022
- 资助金额:
$ 69.8万 - 项目类别:
Project 3: Therapeutic inhibition of splicing through inhibition of protein arginine methylation in leukemia
项目3:通过抑制白血病中蛋白质精氨酸甲基化来治疗性抑制剪接
- 批准号:
10474285 - 财政年份:2021
- 资助金额:
$ 69.8万 - 项目类别:
The Memorial Sloan Kettering Cancer Center SPORE in Leukemia
纪念斯隆凯特琳癌症中心 SPORE 白血病
- 批准号:
10474261 - 财政年份:2021
- 资助金额:
$ 69.8万 - 项目类别:
Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia
靶向急性髓系白血病中的 RNA 结合蛋白网络
- 批准号:
10171812 - 财政年份:2020
- 资助金额:
$ 69.8万 - 项目类别:
Interrogating the minor spliceosome to understand and treat leukemia
研究小剪接体以了解和治疗白血病
- 批准号:
10210368 - 财政年份:2020
- 资助金额:
$ 69.8万 - 项目类别:
Interrogating the minor spliceosome to understand and treat leukemia
研究小剪接体以了解和治疗白血病
- 批准号:
10434705 - 财政年份:2020
- 资助金额:
$ 69.8万 - 项目类别:
Interrogating the minor spliceosome to understand and treat leukemia
研究小剪接体以了解和治疗白血病
- 批准号:
10669013 - 财政年份:2020
- 资助金额:
$ 69.8万 - 项目类别:
相似国自然基金
烯丙基叠氮动态平衡混合物的动态动力学拆分
- 批准号:22371245
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
低共熔溶剂的碱性调控及高效分离油酚混合物的机制研究
- 批准号:22308216
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
复杂混合物二维HSQC图谱精确去卷积分析方法研究
- 批准号:22374012
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
诱导契合金属有机框架分离C3轻烃混合物
- 批准号:22301102
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
高黏度不挥发组分在混合物气泡生长及脱离过程中的扩散行为及非平衡效应
- 批准号:52376001
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Charting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkit
通过多组学单细胞工具包绘制 SF3B1 突变克隆造血 (CH) 和骨髓增生异常综合征 (MDS) 的分化拓扑图
- 批准号:
10570240 - 财政年份:2022
- 资助金额:
$ 69.8万 - 项目类别:
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics.
加勒比西班牙裔混合人群华法林剂量处方的基因组方法。
- 批准号:
8881301 - 财政年份:2014
- 资助金额:
$ 69.8万 - 项目类别:
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics.
加勒比西班牙裔混合人群华法林剂量处方的基因组方法。
- 批准号:
9305775 - 财政年份:2014
- 资助金额:
$ 69.8万 - 项目类别:
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics.
加勒比西班牙裔混合人群华法林剂量处方的基因组方法。
- 批准号:
8627740 - 财政年份:2014
- 资助金额:
$ 69.8万 - 项目类别:
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics.
加勒比西班牙裔混合人群华法林剂量处方的基因组方法。
- 批准号:
9107895 - 财政年份:2014
- 资助金额:
$ 69.8万 - 项目类别: